Greenwood Capital Associates LLC trimmed its position in CONMED Co. (NYSE:CNMD – Free Report) by 2.7% during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 5,862 shares of the company’s stock after selling 161 shares during the quarter. Greenwood Capital Associates LLC’s holdings in CONMED were worth $401,000 at the end of the most recent quarter.
Several other hedge funds have also recently bought and sold shares of the business. GAMMA Investing LLC raised its holdings in shares of CONMED by 93.6% during the 4th quarter. GAMMA Investing LLC now owns 726 shares of the company’s stock valued at $50,000 after buying an additional 351 shares during the period. CWM LLC raised its position in shares of CONMED by 36.1% during the 3rd quarter. CWM LLC now owns 1,251 shares of the company’s stock valued at $90,000 after acquiring an additional 332 shares in the last quarter. Pacer Advisors Inc. lifted its position in shares of CONMED by 41.4% in the 4th quarter. Pacer Advisors Inc. now owns 1,656 shares of the company’s stock worth $113,000 after buying an additional 485 shares during the last quarter. nVerses Capital LLC lifted its holdings in CONMED by 566.7% in the third quarter. nVerses Capital LLC now owns 2,000 shares of the company’s stock worth $144,000 after acquiring an additional 1,700 shares during the last quarter. Finally, ZWJ Investment Counsel Inc. acquired a new position in CONMED during the 3rd quarter valued at approximately $206,000.
CONMED Stock Performance
CONMED stock opened at $72.98 on Wednesday. The firm’s 50 day simple moving average is $70.62 and its 200-day simple moving average is $70.19. The company has a debt-to-equity ratio of 1.01, a current ratio of 2.27 and a quick ratio of 1.06. CONMED Co. has a fifty-two week low of $61.05 and a fifty-two week high of $88.60. The company has a market cap of $2.25 billion, a P/E ratio of 17.33, a price-to-earnings-growth ratio of 1.04 and a beta of 1.46.
CONMED Dividend Announcement
Wall Street Analysts Forecast Growth
A number of research analysts have issued reports on the stock. Needham & Company LLC reissued a “buy” rating and set a $97.00 target price on shares of CONMED in a research note on Thursday, October 31st. StockNews.com cut CONMED from a “buy” rating to a “hold” rating in a research note on Friday, November 8th. Two analysts have rated the stock with a hold rating and four have issued a buy rating to the company. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $79.80.
Get Our Latest Stock Report on CNMD
CONMED Profile
CONMED Corporation, a medical technology company, develops, manufactures, and sells surgical devices and related equipment for surgical procedures worldwide. The company offers orthopedic surgery products, including BioBrace, TruShot with Y-Knot All-In-One Soft Tissue Fixation System, Y-knot All-Suture Anchors, and Agro Knotless Suture Anchors, which provide clinical solutions to orthopedic surgeons for the augmentation and repair of soft tissue injuries, as well as provides supporting products that enable surgeons to perform minimally invasive sports medicine surgeries.
Read More
- Five stocks we like better than CONMED
- Which Wall Street Analysts are the Most Accurate?
- Rocket Lab’s Growth Strategy: Small Rockets, Massive Potential
- Find and Profitably Trade Stocks at 52-Week Lows
- Goldman Sachs vs. Morgan Stanley—Which Stock Has More Upside?
- 3 Dividend Kings To Consider
- 3 Reasons Bulls Will Win on Super Micro Computer Stock
Want to see what other hedge funds are holding CNMD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for CONMED Co. (NYSE:CNMD – Free Report).
Receive News & Ratings for CONMED Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CONMED and related companies with MarketBeat.com's FREE daily email newsletter.